- Home
- GTN vs CELC Comparison
GTN vs CELC Comparison
Compare GTN & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTN
- CELC
- Stock Information
- Founded
- GTN 1897
- CELC 2011
- Country
- GTN United States
- CELC United States
- Employees
- GTN N/A
- CELC N/A
- Industry
- GTN Broadcasting
- CELC Medical Specialities
- Sector
- GTN Industrials
- CELC Health Care
- Exchange
- GTN Nasdaq
- CELC Nasdaq
- Market Cap
- GTN 463.2M
- CELC 440.0M
- IPO Year
- GTN N/A
- CELC 2017
- Fundamental
- Price
- GTN $5.94
- CELC $52.65
- Analyst Decision
- GTN Strong Buy
- CELC Strong Buy
- Analyst Count
- GTN 4
- CELC 6
- Target Price
- GTN $6.88
- CELC $46.50
- AVG Volume (30 Days)
- GTN 1.8M
- CELC 2.8M
- Earning Date
- GTN 08-08-2025
- CELC 08-14-2025
- Dividend Yield
- GTN 5.40%
- CELC N/A
- EPS Growth
- GTN 1482.23
- CELC N/A
- EPS
- GTN 1.53
- CELC N/A
- Revenue
- GTN $3,549,000,000.00
- CELC N/A
- Revenue This Year
- GTN N/A
- CELC N/A
- Revenue Next Year
- GTN $14.63
- CELC N/A
- P/E Ratio
- GTN $3.87
- CELC N/A
- Revenue Growth
- GTN 7.03
- CELC N/A
- 52 Week Low
- GTN $2.91
- CELC $7.58
- 52 Week High
- GTN $6.16
- CELC $53.86
- Technical
- Relative Strength Index (RSI)
- GTN 69.50
- CELC 92.80
- Support Level
- GTN $3.50
- CELC $38.00
- Resistance Level
- GTN $6.09
- CELC $53.40
- Average True Range (ATR)
- GTN 0.37
- CELC 3.29
- MACD
- GTN 0.16
- CELC 0.96
- Stochastic Oscillator
- GTN 97.68
- CELC 94.82
About GTN Gray Television Inc.
Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.